Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the April 22, 2010 joint meeting of the Anesthetic and Life Support Drugs and the Drug Safety and Risk Management Advisory Committees meeting to discuss the New Drug Application for Acurox(R) (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
The FDA panel stated, "Although the Acurox formulation includes a nasal irritant to deter abuse by nasal inhalation, this may not prevent an initial attempt of abuse since the formulation does not prevent from crushing the tablets and the drug abuser may not have any knowledge of the irritancy prior to snorting the crushed Acurox. Additionally, we question if the deterrent properties of this irritant could be abated through pre-treating with other substances/drugs which have nasal numbing properties, prior to the snorting of crushed Acurox. We recommend consideration be given during review of the application as to whether these known methods of abuse will be effectively impacted by the abuse deterrents in the Acurox formulation."
Shares of Acura dropped more than 21%, shedding $1.67 to end the day at $6.23.
CytRx Corporation (NASDAQ: CYTR), moved higher today after the biopharmaceutical company specializing in oncology, today announced that bafetinib (formerly known as INNO-406) has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of chronic myeloid leukemia (CML). The positive opinion of the COMP has now been forwarded to the EU commission for final approval and publication in the community register. Bafetinib also has been granted Orphan Drug Status for the treatment of Philadelphia chromosome-positive (Ph+) CML by the U.S. Food and Drug Administration (FDA).
CytRx recently announced plans to begin three Phase 2 proof-of-concept open-label clinical trials with bafetinib. The clinical trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL) is expected to commence in the first half of 2010, and clinical trials in patients with advanced prostate cancer and glioblastoma multiforme (a common and aggressive type of primary brain tumor) are expected to commence in the second half of 2010.
Shares of CytRx surged more than 11% or 12 cents, closing the day at $1.15. Volume was heavy as more than 6 Million shares traded hands.
In other news Tuesday:
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers. In the pre-clinical study, fifty percent of mice in the combination therapy group (n=10) had complete regressions of primary tumors and metastases at regional and distant sites. Nab-paclitaxel plus bevacizumab was shown to inhibit tumor growth by 100%, and reduced the incidence of lymph node and lung metastases by 50% and 87%, respectively. The findings were discussed at the 101st Annual Meeting of the American Association for Cancer Research (AACR).
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced plans to initiate a Phase 1 single-dose clinical trial of the Company’s compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
"This IND is the result of a number of years of research, planning and collaboration. Acorda’s clinical, preclinical and regulatory teams have done an outstanding job designing a development program to explore the potential of GGF2 in heart failure," said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. "GGF2 may represent a new approach to treating heart failure, and may also have potential applications in neurology, which we hope to investigate in subsequent clinical studies."
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), today presented a poster on dual Erk/PI3K inhibitors and made an oral presentation on its selective Erk inhibitors, at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries. The four studies have achieved the Company’s enrollment targets, with a total of approximately 35 adult and adolescent patients with aHUS.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC). These new pre-clinical data demonstrate – for the first time – that treatment with an RNAi therapeutic can result in regression of pre-existing pathogenic TTR deposits in peripheral tissues. Additional pre-clinical data presented at the meeting demonstrated the potential application of TTR-specific siRNA for the treatment of ocular disease in ATTR.
American Medical Alert Corp. (NASDAQ: AMAC) a provider of healthcare communication services and advanced telehealth monitoring technologies, today announced that its Telephony Based Communication Services received a large award to provide clinical contact management services and brand support for an internationally recognized pharmaceutical manufacturer. AMAC’s PhoneScreen is a leader in the field of patient recruitment, retention and contact center services. The award is expected to generate approximately one million dollars in revenue over the term of the contract and is expected to commence service on or around July 2010 and run into 2011.
AngioDynamics (NASDAQ:ANGO) today announced the first patient treatment and growing enrollment in a pilot study of the use of the Company’s NanoKnife Irreversible Electroporation (IRE) System in the treatment of early stage hepatocellular carcinoma (HCC), or primary liver cancer. This clinical trial is being conducted under the supervision of Professor Jordi Bruix of the Barcelona Clinic Liver Cancer Group of the University of Barcelona and Professor Riccardo Lencioni of the University of Pisa School of Medicine.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor – AP26113 – showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.
Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer (NSCLC) and neuroblastomas, as well as anaplastic large cell lymphoma. Since ALK is generally not expressed in normal adult tissues, it represents a highly promising molecular target for cancer therapy.
Arrayit Corporation (OTCBB:ARYC), a leader in life sciences and healthcare technology, announced today that members of Arrayit management will present at the Southern California Investment Association (SCIA) Summer Capital Conference in Irvine, California on Saturday, June 5, 2010.
ATS Medical, Inc. (Nasdaq:ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced the first commercial implant of the ATS 3f® Aortic Bioprosthesis was recently completed by Liu Zhi Gang, MD at Fu Wai Hospital in Beijing, China. Fu Wai Hospital is the largest cardiac surgery center in Asia and a full line of ATS products are utilized by their surgeons. ATS received permission from the Chinese State Food and Drug Administration (SFDA) to market the ATS 3f Aortic Bioprosthesis in March. "The ATS 3f Aortic Bioprosthesis is much easier to implant than other stentless valves. This is especially important in the small sizes," stated Dr. Liu. A size 23 mm 3f Aortic Bioprosthesis was implanted with a resulting mean pressure gradient of 5 mmHg, which is considered an excellent hemodynamic performance for the smaller size aortic annulus.
Bovie Medical Corporation (AMEX: BVX), edged higher today after the manufacturer and marketer of electrosurgical products, announced it has been awarded a contract by the General Services Administration (GSA). Bovie’s Federal Supply Schedule (FSS) was awarded by the Office of Acquisition and Materiel Management's National Acquisition Center (NAC), located in Hines, Illinois. The NAC is the largest combined contracting entity within the Department of Veterans Affairs (VA) and is responsible for supporting the health care requirements of the VA as well as the needs of other Government agencies. The initial contract period is for five years..
BioDelivery Sciences International, Inc. (Nasdaq:BDSI), a specialty pharmaceutical company, announced that it has entered into a definitive securities purchase agreement with a group of select institutional investors to purchase US$10 million of its securities in a registered direct offering. No placement agent was utilized in connection with the offering.Under the terms of the securities purchase agreement, BDSI will sell an aggregate of 2,824,858 shares of its common stock at a price of US$3.54 per share and issue warrants to acquire an aggregate of 1,412,429 shares of common stock, which warrants will have an exercise price of $4.67 per share.
Bio-Matrix Scientific Group Inc. (OTC.BB:BMSN) today announced the elimination of an additional $1,109,309 in obligations during the quarter ended March 31, 2010. These obligations, including $251, 528 owed on loans made to BMSN by a company controlled by Chairman & CEO Dr. David Koos as well as $304,500 in accrued salaries, were satisfied through the issuance of 17,337,728 shares of common stock. Dr. Koos stated, "I believe the future of Bio-Matrix Scientific Group Inc. is bright. Our majority owned subsidiary, Entest BioMedical, Inc. is making what I believe to be great strides in developing revolutionary new therapies utilizing stem cells."
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), announced that it has established a $25 million credit facility with Silicon Valley Bank and up to $4 million in convertible debt with Partners for Growth. Proceeds will be used to consolidate existing outstanding debt, provide working capital for growth and for general corporate purposes.
Celsion Corporation (Nasdaq:CLSN) today announced that Dr. Thanjavur S. Ravikumar, from the Geisinger Health System and a principal investigator of the Phase I ThermoDox® dose escalation trial, gave an oral presentation at the Liver Tumors Panel session of the 9th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA) in Buenos Aires, Argentina. The presentation, titled "A Phase I Trial of ThermoDox® in Patients Undergoing Radiofrequency Ablation (RFA) of Liver Tumors," provided a summary of the data as well as illustrative patient case studies. The trial results not only support the use of ThermoDox® plus RFA for the treatment of primary liver cancer, but also provide supportive evidence for Celsion to evaluate the effects of ThermoDox in patients with colorectal liver metastases (CRLM).
Cord Blood America, Inc. (OTC Bulletin Board:CBAI.ob),announced that it has signed a Definitive Supplier Agreement with a well respected, accredited, tissue bank providing placenta collection services for therapeutic transplantation, and Cord Blood America is already filling orders.
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced the presentation of preclinical results for several of its pipeline compounds during the American Association of Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, DC.
DARA BioSciences, Inc. (Nasdaq:DARA) announced today that the company has been selected by the Scientific Programme Committee to present results from its Phase 2 study at the Congress on May 29, 2010 in Athens, Greece..
Dyax Corp. (NASDAQ: DYAX) announced today that it has sold its rights to royalties and other payments related to the commercialization of Xyntha by Pfizer, Inc., a licensee under the Company’s phage display Licensing and Funded Research Program (LFRP), to an investment fund managed by Paul Capital Healthcare. Under the terms of this sale, Dyax received an upfront cash payment of $10 million and will be eligible to receive milestone payments totaling up to $2 million based on Xyntha sales in 2010 and 2011.
Genta Incorporated (OTCBB: GETA) moved higher today after the company announced the presentation of initial results from the first human use of a gallium-containing compound to treat serious infection. In a patient with cystic fibrosis and a highly resistant lung infection, who has been treated over a 2-year period, high concentrations of gallium were achieved in sputum. Moreover, sputum concentrations were higher than simultaneous concentrations in blood and continued to rise even after treatment had been stopped. Measured concentrations in sputum equaled or exceeded concentrations that have been reported lethal to bacteria in laboratory tests. "These data show that gallium is preferentially concentrated in sputum of infected lungs," said Dr. Raymond P. Warrell, Jr., Genta’s Chief Executive Officer. "High levels were achieved and sustained during short courses of treatment -- an especially promising result that should obviate any need to consider direct inhalation. A new clinical trial to formally evaluate IV gallium nitrate in patients with cystic fibrosis will begin next month. These preliminary data also suggest that our oral gallium-containing compound may be useful for this purpose as chronic therapy."
Gilead Sciences, Inc. (Nasdaq:GILD) provided an update today on the development of the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals’ investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride, 25 mg). As part of its First Quarter 2010 earnings call, Johnson & Johnson, which owns Tibotec Pharmaceuticals, announced today that the two pivotal Phase III studies evaluating TMC278 as a treatment for HIV in treatment-naïve patients met the primary efficacy objective of non-inferiority as compared to efavirenz based on the proportion of patients achieving HIV RNA levels of less than 50 copies/mL at 48 weeks. Johnson & Johnson also announced that full study results will be presented at a scientific meeting later this year, and that the submission of TMC278 for regulatory review is on track for the third quarter of this year. In a seperate release the company announced that is stopping its ongoing Phase II clinical trial of GS 9450, an investigational caspase inhibitor, in patients with chronic hepatitis C.
Haemonetics Corporation (NYSE:HAE) announced today that Neoteric Technology Ltd, a corporate acquisition in 2009, currently doing business as Haemonetics Canada, LTD, was named the LifeSciences British Columbia Medical Device Company of the Year. In particular, the award recognized the revolutionary BloodTrack® blood transfusion and inventory management system. The BloodTrack suite is comprised of eight solutions, including the HemoSafe automated blood dispensing system and BloodTrack Tx, a bedside point-of-care system that utilizes the latest mobile bar code technology to ensure that the right blood is transfused to the right patient. Each BloodTrack solution is integrated into BloodTrack Manager, a central dashboard that provides hospitals with a comprehensive, real-time view of their entire transfusion service.
Human Genome Sciences, Inc. (Nasdaq: HGSI) fell today after the company, along with GlaxoSmithKline PLC (NYSE:GSK) announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The results showed that at Week 76 in the BLISS-76 study, belimumab plus standard of care showed higher response rates compared with placebo plus standard of care as measured by the SLE Responder Index; however, this secondary endpoint did not reach statistical significance. Study results, however, showed that belimumab continued to be generally well tolerated, as demonstrated by a similar rate of discontinuations due to adverse events across treatment groups, with overall adverse event rates comparable between belimumab and placebo treatment groups. Shares fell more than $2.00 on the news.
Hypertension Diagnostics, Inc. (OTC.BB:HDII) jumped higher today as the company reported that new medical research data published in the American Journal of Epidemiology provides significant evidence that Hypertension Diagnostics, Inc.'s (HDI) non-invasive CardioVascular Profiling test, which measures the elasticity of the small blood vessels, is the earliest and best predictor of hypertension when compared to several more established and expensive testing methodologies used by physicians and cardiologists..
Immunomedics, Inc. (Nasdaq:IMMU), today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. "We have now demonstrated that the blood assay for PAM4-protein can not only detect early-stage pancreatic cancer, as has recently been reported by us, but may also predict a lack of response to therapy or an early relapse," remarked Cynthia L. Sullivan, President and CEO. "As a result, we believe we may be one step closer to offering an individualized approach for the management of this lethal disease," Ms. Sullivan added.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it earned a $6.5 million payment from Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) as a result of Roche progressing RG7348 into a Phase I clinical trial for the treatment of hepatitis C viral (HCV) infection. The milestone payment arises from a 2008 collaboration and license agreement between Roche and Metabasis Therapeutics, Inc. Ligand acquired Metabasis in January 2010. Ligand’s net proceeds from the milestone payment will be approximately $2.3 million after paying $4.2 million to others including holders of the Ligand-issued "Roche" CVR.
Mannatech, Incorporated (NASDAQ: MTEX), a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, announced the results of an independent study that demonstrated its proprietary Ambrotose-complex and Advanced Ambrotose-powder exerted prebiotic effects. Its findings determined both Ambrotose complex and Advanced Ambrotose powder exhibited good selective fermentability throughout the entire colon, positive and selective bifidogenic effects and also demonstrated the possibility of enhancing species belonging to Bacteroidetes.
Marshall Edwards, Inc. (NASDAQ:MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, today announced that the Company has received notice from the Nasdaq Listing Qualifications Panel that it has regained compliance with the $1.00 minimum closing bid price requirement in accordance with the Nasdaq Listing Rules for continued listing on the Nasdaq Global Market.
Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of preclinical data characterizing MPI-0486348, the lead compound in the company's Nicotinamide phosphoribosyltransferase (Nampt) inhibitor pre-clinical program at the American Association for Cancer Research (AACR) 101st Annual Meeting in Washington, D.C.
NeoPharm, Inc. (OTC: NEOL.PK), moved higher today after the company announced that it has started enrolling patients in its Phase II clinical trial for liposome entrapped docetaxel (LE-DT), as a frontline treatment of pancreatic cancer patients with locally advanced or metastatic disease. LE-DT is a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere.
"Unfortunately, pancreatic cancer is one of the cancers which has no effective treatment. We are hoping that this new modality of treatment with LE-DT will bring some hope and treatment options to those unfortunate patients" commented Dr. Aquilur Rahman, President and Chief Executive Officer of NeoPharm.
"Following the very impressive results of the LE-DT Phase I trial, this open-label, Phase II study will help us determine the antitumor effect of LE-DT in this lethal disease. Progression Free Survival and Overall Survival along with a number of biologic markers such as CA-19-9 and SPARC expression, which are potentially related to the response of the disease, will be monitored. In addition, we will be evaluating the quality of life in these patients with metastatic disease."
Neuralstem, Inc. (NYSE Amex: CUR) shot higher on heavy volume and no apparent news. The stock was up 18.42% or 42 cents to $2.70. Volume of over 3 million shares was more than twenty times the daily average.
Ohr Pharmaceutical Inc. (OTC.BB:OHRP) announced today that it has established its headquarters in New York City. The Company was previously based in Salt Lake City on an interim basis.
Prana Biotechnology (NASDAQ:PRAN) (ASX:PBT) today announced that it is finalising plans to commence a definitive Phase IIb trial of its lead Alzheimer's disease drug, PBT2, before the end of this year.
The Phase IIb trial will involve 525 patients with mild to moderate Alzheimer's disease. Treatment will be over a period of 12 months, with the key performance measure being cognition (including ADAS Cog* and Executive Function tests from the NTB*). The trial, a double blind placebo controlled study, will test the efficacy of 2 doses of PBT2 (250mg and 100mg). "We are excited by this protocol because we already know how patients benefited from a 250mg dose of PBT2 in just 12 weeks, so we are confident the benefit will be even stronger and more pronounced over a 12 month trial," said Mr. Kempler. "This trial is all about cognition and helping patients."
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) jumped up more than 5% after the company today announced interim results from the first 3 subjects enrolled in a Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and significant visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.
Seattle Genetics, Inc. (Nasdaq: SGEN) moved higher today after announcing that Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties’ existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics’ ADC technology with antibodies against targets selected by Genentech. Genentech is responsible for research, product development, manufacturing and commercialization. Seattle Genetics is entitled to receive fees, progress-dependent milestone payments and royalties on net sales of any resulting ADC products. Seattle Genetics has generated approximately $120 million through ADC technology license agreements with leading biotechnology and pharmaceutical companies. ADCs utilize the targeting ability of monoclonal antibodies to deliver potent, cell-killing payloads to specific cells.
STERIS Corporation (NYSE:STE) today announced it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the terms of a consent decree regarding its SYSTEM 1® liquid chemical sterilization system. Included in the agreement is a Transition Plan with a Rebate Program for current SYSTEM 1 Customers in the U.S. The consent decree is subject to approval by the U.S. District Court for the Northern District of Ohio.
In general, the agreement resolves the government’s complaint relating to the FDA’s allegations in its May 2008 warning letter, prohibits the sale of liquid chemical sterilization or disinfection products that do not have FDA clearance, formalizes STERIS’s Rebate Program and the continued support of SYSTEM 1 Customers during the FDA authorized transition time period, and describes various process and compliance issues.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), edged higher today after the company announced preclinical results presented at the American Association for Cancer Research (AACR) 101st Annual Meeting that support correlative markers for elesclomol anti-cancer activity. In addition, results were presented by Synta collaborators showing that elesclomol demonstrates activity in cisplatin-resistant lung cancer models.
"The results presented today are encouraging and support the continued clinical development of elesclomol," said Vojo Vukovic, M.D., Ph.D., Senior Vice President and Chief Medical Officer, Synta. "Our improved understanding of the activity of elesclomol will allow us to concentrate our clinical efforts on those patients who are most likely to benefit from treatment."
Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced multiple preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research (AACR) Annual Meeting." These are very exciting preclinical results which extend our understanding of the mechanism of action and antitumor activity of TH-302," said Charles Hart, Ph.D., Threshold's vice president of biology. "Our translational observations provide further support that TH-302 is selectively targeting tumor hypoxia and continue to inform the design of our clinical programs."
Viking Systems (OTCBB:VKNG) moved up today as the company announced that preclinical surgical video created using a Viking Systems' "Next Generation" 3DHD prototype visualization system displayed on a Sony prototype medical grade 3DHD monitor was enthusiastically received during The 12th World Congress of Endoscopic Surgery.
Vicor Technologies, Inc. (OTC.BB:VCRT), today announced the results of a pilot study to test the ability of its PD2i nonlinear algorithm to detect acute hypovolemia. "We are very encouraged by the results achieved by the PD2i in this small pilot study, which suggest the prospect of incorporating the PD2i nonlinear algorithm into a noninvasive diagnostic for use in identifying patients who are bleeding internally stated David H. Fater, CEO. The company is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including sudden cardiac death and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.
Wellstar International Inc. (OTCBB: WLSI) has announced they will be installing a TMI Imaging system in a Doctor’s office in Torrance, California. The system will be used primarily for the detection of inflammation and neuropathy. The practice specializes in treating patients with diabetes. Neuropathy, inflammation and lack of circulation are very prevalent with Diabetes. The TMI System will be able to detect and track the inflammation, neuropathy and possible deep tissue damage caused by lack of circulation.
Winner Medical Group Inc. (Nasdaq:WWIN), a leading manufacturer of medical dressings, medical disposables and non-woven PurCotton(R) materials for the medical and consumer products industries, announced today that since January 1, 2010, it has opened nine PurCotton(R) chain stores, and an additional eight new stores will be opened by the end of April in Shenzhen, Guangdong province, China.
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), tracked higher as the company announced today that preclinical data on the novel organic arsenic darinaparsin (Zinapar, or ZIO-101) were presented at the American Association for Cancer Research (AACR) Annual Meeting .
Abbott (NYSE:ABT) today announced the successful completion of the tender offer by its wholly owned subsidiary Amber Acquisition Inc. to purchase all of the outstanding shares of common stock of Facet Biotech.
Aoxing Pharmaceutical Company Inc. (NYSE Amex:AXN) today announced that Aoxing Pharma is invited to present at Deutsche Bank Access Asia Conference 2010 in Singapore from May 10 to May 13, 2010.
Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.
Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced it has received its first handheld integrated optical biosensor (IOBS) unit from Los Alamos National Security, LLC.
China Pharmaceuticals, Inc. (OTC Bulletin Board: CFMI) today announced financial results for its fiscal year ended December 31, 2009.
CorMedix Inc.(NYSE Amex: CRMD.U), a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiorenal disease, today announced that the U.S. Patent and Trademark Office has issued a patent for the use of Neutrolin® for preventing infection and clotting in hemodialysis catheters.
CVS Caremark (NYSE:CVS) today announced results of a survey of the company's specialty pharmacy patients that provides insights into their views on medication adherence and their perceptions about the role of their specialty pharmacy.
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that preclinical data in neuroblastoma for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR), currently being held in Washington, DC.
Medical Marijuana Inc (PINKSHEETS:MJNA) has begun the pre-launch of its newest division, The Hemp Network.
RAE Systems Inc. (NYSE Amex: RAE) today announced it will showcase its top-of-the-line gas-detection solutions -- including its industry-leading wireless systems -- at the Fire Department Instructors Conference (FDIC 2010) in Indianapolis, Ind. April 19-24 with a "dramatic" enactment of an hazardous-materials incident and real-time response.
Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines, today announced the appointment of Dr. Changxiong Sun and Mr. Bingchun Wu to its Board of Directors as independent directors effective April 19.Dr. Sun and Mr. Wu will join the Company's Audit Committee, which is chaired by independent director Mr. Sean Shao.
SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that it will release its 2010 first quarter financial results on Monday, April 26, 2010.
Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) held its annual meeting of stockholders today in Chapel Hill, N.C.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has given notice of its intention to redeem all of the outstanding Floating Rate Convertible Senior Debentures due 2033 (the "2033 Convertible Notes").
Vermillion, Inc. (Pink Sheets: VRML) today announced that the United States Bankruptcy Court for the District of Delaware approved the final fee application in the case.
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 35th Annual Deutsche Bank Health Care Conference.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.